IP Library › Granted Patent US 7,662,929
Granted Patent B2
US 7,662,929 · App. 10/574,903 · Granted Feb 16, 2010

Antibody that specifically binds hyaluronan synthase

Assignee: Alchemia Oncology Pty Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,662,929
App. No.
10/574,903
Granted
Feb 16, 2010
Kind
B2
Abstract

Modulation of Hyaluronan (HA) synthesis and degradation is disclosed by compounds and compositions that are capable of reducing the level of hyaluronan synthase (HAS) or hyaluronidase (HYAL) or the function or activity of HAS or HYAL. The compounds and compositions can also inhibit the expression of genetic material encoding these enzymes. The compounds and compositions comprise nucleic acid molecules and interactive molecules such as antibodies, small molecule inhibitors and substrate analogs of HAS and HYAL. The compounds and compositions are useful in the prophylaxis and/or treatment of inflammatory disorders including hyperproliferative conditions, such as but not limited to, cancer and psoriasis.

Claims (5)

1. An isolated antibody which reduces the level of hyaluronan synthase (HAS) activity wherein said antibody specifically binds targeted antigen of SEQ ID NO: 25 within HAS1.

2. The isolated antibody of claim 1 wherein the HAS activity is selected from the group consisting of HAS1, HAS2 and HAS3 activity.

3. The isolated antibody of claim 1 or 2 wherein the antibody is selected form a monoclonal antibody, polyclonal antibody, and antigen-binding fragment and a humanized antibody.

4. The isolated antibody of claim 3 wherein the antibody is a monoclonal antibody or an antigen-binding fragment thereof.

5. A pharmaceutical composition comprising an antibody of claim 1 and one or more pharmaceutically acceptable carriers and/or diluents.

Assignments (4)
CORRECTION OF EXECUTION DATE, PREVIOUSLY RECORDED AT 022702/0081 Recorded Sep 26, 2012
From: ALCHEMIA ONCOLOGY LIMITED
To: ALCHEMIA ONCOLOGY PTY LIMITED
Reel/Frame 029044/0599 →
CHANGE OF NAME Recorded May 18, 2009
From: ALCHEMIA ONCOLOGY LIMITED
To: ALCHEMIA ONCOLOGY PTY LIMITED
Reel/Frame 022702/0081 →
CHANGE OF NAME Recorded Mar 12, 2007
From: MEDITECH RESEARCH LIMITED
To: ALCHEMIA ONCOLOGY LIMITED
Reel/Frame 018989/0523 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2007
From: BROWN, TRACEY JEAN; BROWNLEE, GARY RUSSELL
To: MEDITECH RESEARCH LIMITED
Reel/Frame 018943/0446 →
Priority Claims (2)
AU 2003905551 · Oct 10, 2003 · national
AU 2003906658 · Dec 1, 2003 · national
Continuity (1)
Related Publication 20070286856A1 · Dec 13, 2007